Pharmacological inhibition of the ALK axis elicits therapeutic potential in Consensus Molecular Subtype 1 colon cancer patients
M. Mazzeschi, M. Sgarzi, D. Romaniello, V. Gelfo, C. Cavallo, S. Santi, M. Fiorentino, G. D'Uva, B. Gyorffy, R. Palmer, M. Lauriola
This study shows that ALK inhibition improves outcomes in CMS1 colon cancer patients by reducing cell proliferation and enhancing cell adhesion.
bioRxiv · Oct 7, 2020 · PreprintCancer Biology